Literature DB >> 24727755

Markets, venture investors and big pharma interest in RNAi soars.

Aaron Bouchie.   

Abstract

Mesh：

Year:  2014        PMID： 24727755     DOI： 10.1038/nbt0314-203

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Unlocking the money-making potential of RNAi.

Authors:  Ken Howard
Journal:  Nat Biotechnol       Date:  2003-12       Impact factor: 54.908

2.  RNAi momentum fizzles as pharma shifts priorities.

Authors:  Charles Schmidt
Journal:  Nat Biotechnol       Date:  2011-02       Impact factor: 54.908
  2 in total
  4 in total

1.  RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise.

Authors:  Manisit Das; Sara Musetti; Leaf Huang
Journal:  Nucleic Acid Ther       Date:  2018-12-18       Impact factor: 5.486

2.  Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.

Authors:  Hongyan He; Xiyan Nan; Shuang Liu; Liangren Zhang; Zhenjun Yang; Yun Wu; Lihe Zhang
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

Review 3.  Viral Delivery of dsRNA for Control of Insect Agricultural Pests and Vectors of Human Disease: Prospects and Challenges.

Authors:  Anna Kolliopoulou; Clauvis N T Taning; Guy Smagghe; Luc Swevers
Journal:  Front Physiol       Date:  2017-06-14       Impact factor: 4.566

Review 4.  Nanoparticles in the clinic.

Authors:  Aaron C Anselmo; Samir Mitragotri
Journal:  Bioeng Transl Med       Date:  2016-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.